neuroendocrine neoplasm
Conditions
Interventions
Gold Standard:Pathological diagnosis
Index test:18F-mFBG PET/CT imaging
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Voluntarily participate in the clinical study and sign a written informed consent prior to the implementation of any trial-related procedures; 2. Life expectancy exceeds 3 months; 3. PPGL or NB that is pathologically confirmed or clinically highly suspected; 4. Newly diagnosed patients or =6 months from the completion of the last anti-tumor therapy; 5. Women and men of reproductive age must agree to use a strict and effective contraceptive method after signing informed consent, during the study period and for 6 months after the end of the trial, during which sperm donation is prohibited for men and egg freezing is prohibited for women. Pregnancy test results for female subjects of childbearing age must be negative within 3 days prior to the first dosing; 6. ECOG score 0-1.
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating patients; 2. Impaired renal function, creatinine clearance less than 40 mL/min; 3. Combined with other primary malignant tumors; 4. Patients who do not sign informed consent or cannot cooperate; 5. ECOG score >= 2 points; 6. Any other circumstances that the investigator determines are not suitable for inclusion in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| maximum standardized uptake; | — |
Secondary
| Measure | Time frame |
|---|---|
| mean standardized uptake;tumor to background ratio; | — |
Countries
China
Contacts
Public ContactYueqi Wang
West China Hospital of Sichuan University
Outcome results
None listed